Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
This year brought wins for artificial intelligence, genomics and gene editing, and breakthroughs in understanding diseases whose underpinnings have long eluded scientists. Here is our selection of critical developments that moved medicine forward in 2023.
This year brought wins for artificial intelligence, genomics and gene editing, and breakthroughs in understanding diseases whose underpinnings have long eluded scientists. Here is our selection of critical developments that moved medicine forward in 2023.
This year brought wins for artificial intelligence, genomics and gene editing, and breakthroughs in understanding diseases whose underpinnings have long eluded scientists. Here is our selection of critical developments that moved medicine forward in 2023.
This year brought wins for artificial intelligence, genomics and gene editing, and breakthroughs in understanding diseases whose underpinnings have long eluded scientists. Here is our selection of critical developments that moved medicine forward in 2023.
This year brought wins for artificial intelligence, genomics and gene editing, and breakthroughs in understanding diseases whose underpinnings have long eluded scientists. Here is our selection of critical developments that moved medicine forward in 2023.
This year brought wins for artificial intelligence, genomics and gene editing, and breakthroughs in understanding diseases whose underpinnings have long eluded scientists. Here is our selection of critical developments that moved medicine forward in 2023.
Evidence supports the use of primary HPV testing to accelerate the global elimination of cervical cancer, but such recommendations must be viewed in the context of the fragile healthcare systems and complex implementation challenges in low-income and lower-middle income countries.
The authors discuss how screening strategies, treatment approaches and precision oncology are evolving in China and outline trends and priorities in the drug development and regulatory landscape.
Glial cells influence brain function and disease progression. This study identifies signals that elicit hemorrhage-specific glia plasticity, including proliferation and the acquisition of neural stem cell properties. It thereby sets a foundation for aligning glia reactivity with disease progression and for attempting to use this endogenous stem cell pool for brain repair.
Research participants often do not represent the target population for treatment. Systematic exclusion of particular groups limits the generalizability of research and perpetuates health inequalities. The REP-EQUITY toolkit guides representative and equitable inclusion in research. Its use may promote trust between communities and research institutions and improve the applicability of research findings.
Nature Medicine asks leading researchers to name their top clinical trial for 2024, from base editing and a vaccine against HIV to artificial intelligence tools for lung cancer and patient triage.
A validated biomarker risk score based on the expression of 34 genes improves risk stratification of patients with meningioma, including prediction of post-operative radiotherapy benefit.
A prognostic model for invasive breast cancer that is based on interpretable measurements of epithelial, stromal, and immune components outperforms histologic grading by expert pathologists. This model could improve clinical management of patients diagnosed with invasive breast cancer and address the concerns of pathologists about artificial intelligence (AI) trustworthiness by providing transparent and explainable predictions.
Nature Medicine asks six leading AI researchers to explain how LLM-powered chatbots are having an impact on health, from virtual nurses to detecting cancer progression.
A study of nearly one million people who underwent a CT scan before 22 years of age finds that the radiation from CT scans increased the risk of hematological malignancies in a dose-dependent manner. These findings highlight the continued need to justify CT scans and minimize radiation doses.
The prevalence of aneuploid cells in miscarried human embryos is higher than previously quoted. Genomic imbalances seem to be less tolerated in the embryoblast than the trophoblast, which indicates that allocation of aneuploid cells to the inner cell mass during blastocyst formation might have a detrimental effect on embryo development.
We find that people with non-suppressible human immunodeficiency virus (HIV) viremia despite antiretroviral therapy (ART) exhibit several distinguishing features. These include expanded CD4+ T cell clones containing HIV proviruses integrated into transcriptionally permissive regions, the presence of certain proviral defects or human leukocyte antigen (HLA)-escape mutations, enhanced survival signatures, and muted interferon and cytotoxic CD8+ T cell responses.
New data show that AI could enhance imaging-based screening for pancreatic cancer; however, its evaluation must be rigorous and adhere to the same standards used for conventional screening.
A phase 1 trial of an IRAK4-targeted protein degrader in patients with chronic inflammatory skin diseases hits an important milestone for the safe application of this drug class beyond oncology.
